vTv Therapeutics Inc., a late-stage biopharmaceutical company, focuses on developing oral small molecule drug candidates intended to treat people living with diabetes and other chronic diseases. Its lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial to treat type 1 diabetes. The company is also investing a range of molecules across various indications for chronic diseases. It has a license agreement Newsoara Biopharma Co., Ltd. to develop and commercialize phosphodiesterase type 4 inhibitors program. vTv Therapeutics Inc. was incorporated in 2015 and is headquartered in High Point, North Carolina. Show more

3980 Premier Drive, Suite 310, High Point, NC, 27265, United States

https://vtvtherapeutics.com

Biotechnology

Healthcare

Start AI Chat

Market Cap

131.1M

52 Wk Range

$14.00 - $44.00

Previous Close

$33.28

Open

$33.01

Volume

61,432

Day Range

$32.86 - $39.40

Enterprise Value

30.71M

Cash

98.5M

Avg Qtr Burn

-5.222M

Insider Ownership

23.60%

Institutional Own.

32.71%

Qtr Updated

09/30/25

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Cadisegliatin (TTP399) Details Type 1 diabetes, Diabetes	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
HPP737 Details Psoriasis, Skin disease/disorder	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Cadisegliatin (TTP399) Details Diabetes, Type 2 diabetes	Phase 2 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
TTP273 (Oral GLP-1R) Details Diabetes, Type 2 diabetes, Cystic fibrosis	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
TTP488 (Azeliragon) (RAGE) Details Frontotemporal dementia with C9orf72 mutation, Dementia, Alzheimer's disease, Neurological disorder	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.